Silo Pharma Buys QwikAgents

Silo Pharma said on April 22 that it bought the assets of Qwikagents.ai and is launching a separate artificial-intelligence business alongside its drug pipeline. (markets.businessinsider.com) Qwikagents is a managed platform for autonomous AI agents, which are software tools built to handle tasks with limited human input. Silo said the platform can be used for research, content generation, scheduling and workflow automation. (financialcontent.com) The company said it will house the business in a dedicated AI subsidiary rather than fold it into its existing biopharma operations. Chief executive Eric Weisblum said the goal is to create a new revenue stream while keeping Silo’s core therapeutic programs moving forward. (finviz.com) Silo is not a pure software company. Its own investor materials describe it as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on stress-induced psychiatric disorders, chronic pain and central nervous system diseases. (silopharma.com 1) (silopharma.com 2) That makes the Qwikagents purchase a sharp expansion beyond the company’s established pitch to investors. In February, Silo announced a share buyback and described itself as a developmental-stage biopharmaceutical company; by April, it was presenting artificial intelligence as a second line of business. (nasdaq.com) (markets.businessinsider.com) Silo said Qwikagents uses smart-routing technology to shift work across multiple AI models in search of lower cost and better performance. The company did not disclose a purchase price, financing terms or revenue contributed by the acquired assets in the announcement distributed April 22. (finviz.com) (markets.businessinsider.com) The market-size pitch came straight from outside forecasts cited by Silo. The company said research firms project the AI-agent market could reach $47 billion to $53 billion by 2030, with annual growth estimates in the 43% to 50% range. (finviz.com) At the same time, Silo said it is still advancing SPC-15, its post-traumatic stress disorder program, toward an investigational new drug application and Phase 1 clinical trials. The company’s pipeline page also lists SP-26 for fibromyalgia and chronic pain, plus preclinical work in Alzheimer’s disease. (investorwire.com) (silopharma.com) What Silo bought, then, was not a biotech tool aimed specifically at drug discovery in the announcement’s wording. It bought a general-purpose AI-agent platform and is using it to open a new business line while it continues to present itself as a biopharma company on Nasdaq. (financialcontent.com) (silopharma.com)